-
17:20
-
16:50
-
16:20
-
15:50
-
15:20
-
14:50
-
14:20
-
13:20
-
12:50
-
12:20
-
11:50
-
11:20
-
10:50
-
10:40
-
10:20
-
09:50
-
09:09
-
08:50
-
08:20
-
07:50
Follow us on Facebook
Morocco launches Semaglutide: a breakthrough treatment for type 2 diabetes
Marrakesh, November 4, 2025 — The pharmaceutical company Novo Nordisk, in partnership with Laprophan Laboratories, has officially launched Semaglutide in Morocco — an innovative medication designed for patients with type 2 diabetes. The announcement was made during a scientific conference in Marrakesh that gathered more than 400 healthcare professionals to discuss integrated strategies for managing diabetes and its complications.
Diabetes remains a major public health issue in Morocco, affecting around 2.6 million people. Complications such as cardiovascular and kidney diseases make effective treatment essential.
Professor Nawal El Ansari, head of the Endocrinology Department at Mohammed VI University Hospital in Marrakesh, stated:
“Semaglutide represents a new standard in diabetes care. Proper management of the disease significantly reduces the risk of severe complications.”
Semaglutide stands out for its once-weekly injection, available in 0.25 mg, 0.5 mg, and 1 mg doses. According to Dr. Olla Al Refai, Managing Director of Novo Nordisk Morocco, the drug offers patients “an easier and more effective way to achieve their therapeutic goals while improving their quality of life.”
The event was attended by Berit Basse, Denmark’s Ambassador to Morocco, who praised the cooperation between Danish and Moroccan medical institutions to advance diabetes care.
Experts such as Professors Bruno Guerci, Asma Chadli, and Paolo Fadini highlighted Semaglutide’s metabolic and cardiovascular benefits, including protection for the heart and kidneys.
Belonging to the GLP-1 agonist class, Semaglutide improves blood sugar control, supports weight loss, and lowers cardiovascular risks. Clinical trials show it significantly reduces major cardiac events beyond its glucose-lowering effect.
Founded in 1923 in Copenhagen, Novo Nordisk is a global healthcare leader specializing in diabetes and chronic disease management, employing over 77,000 people in more than 80 countries.
